Juventas Cell Therapy Ltd.
CD19 CAR-T(Juventas Cell Therapy Ltd.)은 CD19 표적 세포·유전자 치료로, B-cell Malignancy; B-cell Lymphoma 영역에서 개발·상용화 중입니다. 작용기전: CAR-T cells with increasing amounts of antigen-loaded beads yielded a dose-dependent secretion of IFN-γ, whereas non-loaded or MOCK antigen-loaded beads did n. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 88% (ClinicalTrials.gov NCT04002401). 차별점: Novel Hypothermic Preservation Formulation Containing SUL-138 Enables Long-Term Hypothermic Storage of Clinical-Grade CAR-T C.
CD19
B-cell Malignancy; B-cell Lymphoma
Active
CAR-T
adenoviral hemorrhagic cystitis as an uncommon complication after CD19 CAR-T cell therapy
Novel Hypothermic Preservation Formulation Containing SUL-138 Enables Long-Term Hypothermic Storage of Clinical-Grade CAR-T C
CAR-T cells with increasing amounts of antigen-loaded beads yielded a dose-dependent secretion of IFN-γ, whereas non-loaded or MOCK antigen-loaded beads did n
cytokine release syndrome (CRS), neurotoxicity, and infection
CD19 CAR-T cells, cryopreserved CAR-T cells yielded low
resistance mechanisms
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Juventas Cell Therapy Ltd.
CD19 CAR-T(Juventas Cell Therapy Ltd.)은 CD19 표적 세포·유전자 치료로, B-cell Malignancy; B-cell Lymphoma 영역에서 개발·상용화 중입니다. 작용기전: CAR-T cells with increasing amounts of antigen-loaded beads yielded a dose-dependent secretion of IFN-γ, whereas non-loaded or MOCK antigen-loaded beads did n. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 88% (ClinicalTrials.gov NCT04002401). 차별점: Novel Hypothermic Preservation Formulation Containing SUL-138 Enables Long-Term Hypothermic Storage of Clinical-Grade CAR-T C.
CD19
B-cell Malignancy; B-cell Lymphoma
Active
CAR-T
adenoviral hemorrhagic cystitis as an uncommon complication after CD19 CAR-T cell therapy
Novel Hypothermic Preservation Formulation Containing SUL-138 Enables Long-Term Hypothermic Storage of Clinical-Grade CAR-T C
CAR-T cells with increasing amounts of antigen-loaded beads yielded a dose-dependent secretion of IFN-γ, whereas non-loaded or MOCK antigen-loaded beads did n
cytokine release syndrome (CRS), neurotoxicity, and infection
CD19 CAR-T cells, cryopreserved CAR-T cells yielded low
resistance mechanisms
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.